CollPlant Signs Securities Purchase Agreements for approximately NIS 2.2 Million Private Placement

Ness Ziona, Israel, January 18, 2018, CollPlant (TASE: CLPT), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, “rhCollagen”), announced today the signing of investment agreements with three of its current investors, for an approximately NIS 2.2 million private placement. Closing of the transaction is expected next week. The investors, Alpha Capital Anstalt, Docor International B.V and Mr. Ami Sagi, will invest such amount against allocation of 4,344,340 shares of the Company.

About CollPlant

CollPlant is a regenerative medicine company leveraging its proprietary, plant-based recombinant human collagen (rhCollagen) technology for the development and commercialization of tissue repair products, initially for the orthobiologics, 3D Bio-printing of tissue and organs, and advanced wound care markets. The Company’s cutting-edge technology is designed to generate and process proprietary rhCollagen, among other patent-protected recombinant proteins. Given that CollPlant’s rhCollagen is identical to the type I collagen produced by the human body, it offers significant advantages compared to currently marketed tissue-derived collagen, including improved biofunctionality, superior homogeneity and reduced risk of immune response. The Company’s broad development pipeline includes biomaterials indicated for orthopedics and advanced wound healing. Lead products include: Vergenix®STR (Soft Tissue Repair Matrix), for the treatment of tendinopathy; and Vergenix®FG (Flowable Gel) wound filler, for treatment of acute and chronic wounds. CollPlant’s business strategy includes proprietary development and manufacture of tissue repair products and their commercialization and distribution, together with leading third parties, alongside alliances with leading companies for joint development, manufacture and marketing of additional products.

For more information about CollPlant, visit http://www.collplant.com

Contact at CollPlant:
Eran Rotem
Chief Financial Officer
Tel: +972-73-2325600/612
Email: Eran@collplant.com

Contact at Rx Communications Group, LLC:
Paula Schwartz (for US Investors)
Senior Vice President
Tel: +1-917-322-2216
Email: pschwartz@RxIR.com

® 2015 CollPlant Ltd. All rights reserved. Version: CPW 02-16